To ensure ease of doing business, the Central Drugs Standard Control Organization (CDSCO) has waived the provision of procuring "no-objection" certificate (NOC) by pharmaceutical companies for exporting drugs, medical devices and cosmetics across ports in the country.
Previously, licensed manufacturers of drugs and medical devices could export them only to the US, Canada, Japan, Australia and the European Union.
In a notice issued yesterday, the CDSCO said the NOC for licensed manufacturers will be waived if "shipping bills" submitted by the manufacturer include a copy of its "valid licence".
"This is being done to bring ease in drug regulatory practices in India relating to export of drugs, medical devices and cosmetics. All the stakeholders are, however, required to comply with the regulatory requirements of the importing countries as per their specific needs," the notice read.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
